Mucin 4 (8G7) Antibody sc-53945 from Santa Cruz Biotechnology, Inc.

Product Specs
ItemMucin 4 (8G7) Antibody
CompanySanta Cruz Biotechnology, Inc.
Price $333.00Supplier Page View Company Product Page
Catalog Numbersc-53945
Antibody TypePrimary Antibodies
NCBI Gene AliasesASGP, HSA276359, MUC-4
Clone8G7
Quantity100 µg/ml
ApplicationsWB, IP, IF, IHC(P)
Reactivityhuman
Hostmouse
FormatPurified
Conjugate/TagUnconjugated
ClonalityMonoclonal
NCBI Full Gene Namemucin 4, cell surface associated
TargetMucin 4
IsotypeIgG1

Questions and Answers

Can this antibody be used for immunohistochemistry in pancreatic cancer research?

Yes, the Mucin 4 (8G7) Antibody has been utilized in immunohistochemical analyses of orthotopic tumors generated from pancreatic cancer cell lines, as documented in the study by Ayars et al. (2017). In this study, the antibody was used at a dilution of 1:100, indicating its applicability in this context.

What species does this antibody react with, and is it suitable for human tissue studies?

The Mucin 4 (8G7) Antibody is reactive with Homo sapiens (human), making it suitable for studies involving human tissue samples.

Is there any evidence of this antibody being used in Western blotting applications?

While the specific usage of the Mucin 4 (8G7) Antibody in Western blotting is not detailed in the provided information, it is listed among the applications for which the antibody is suitable. Researchers may find it beneficial for detecting MUC4 protein expression in various experimental setups.

How has this antibody been cited in scientific literature?

The Mucin 4 (8G7) Antibody has been cited in 59 scientific articles, indicating its widespread use and recognition in the research community, particularly in studies related to cell biology and cancer research.

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Mucin expression in pancreatic ductal adenocarcinoma cell lines in 2D and 3D cultures: A proteomic and immunocytochemical analysisPLoS OneJuly 16, 2026Yuuki Shichi, Hiroki Tsumoto, Masakazu Fujiwara, Keisuke Nonaka, Yasuko Hasegawa, Seiichi Shinji, Hirofumi Rokutan, Kimimasa Takahashi, Tomio Arai, Yuri Miura, et al.PA0155; ready-to-use), mouse monoclonal anti-MUC4 (8G7; Santa Cruz Biotechnology, Texas, CA, USA; Cat# sc-53945; 1:400), mouse monoclonal anti-MUC5AC (CLH2; Leica Biosystems; Cat# NCL-MUC-5 AC; 1:100), mouse monoclonal

(2) The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal AdenocarcinomaCellsApril 24, 2025Léon Raymakers, Elsemieke M. Passchier, Meggy E. L. Verdonschot, Mitchell Evers, Chilam Chan, Karel C. Kuijpers, G. Mihaela Raicu, I. Quintus Molenaar, Hjalmar C. van Santvoort, Karin Strijbis, et al.antibodies against MUC1 (214D4 & 139H2), MUC4 (clone 8G7, Santa Cruz Biotechnology, Dallas, TX, USA, cat# sc-53945), and MUC16, were provided by Karin Strijbis (Utrecht University). 2.4. TAA Detection Antibody binding

(3) Stepwise progression of invasive mucinous adenocarcinoma based on radiological and biological characteristicsLung cancer (Amsterdam, Netherlands)October 1, 2023Goto E, Takamochi K, Kishikawa S, Hayashi T, Ueda T, Hattori A, Fukui M, Matsunaga T, Suzuki K, Tokyo Metropolitan Innovative Oncology Research Group (TMIG).

(4) MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemiaLeukemia & lymphomaJune 1, 2022Kaumeyer B, Fidai S, Sukhanova M, Yap KL, Segal J, Raca G, Stock W, McNeer J, Lager AM, Gurbuxani S.

(5) Next-generation sequencing analysis suggests varied multistep mutational pathogenesis for endocrine mucin-producing sweat gland carcinoma with comments on INSM1 and MUC2 suggesting a conjunctival originJournal of the American Academy of DermatologyMay 1, 2022Mathew JG, Bowman AS, Saab J, Busam KJ, Nehal K, Pulitzer M.

(6) An integrative histopathological and epigenetic characterization of primary intracranial mesenchymal tumors, FET:CREB-fused broadening the spectrum of tumor entities in comparison with their soft tissue counterpartsBrain pathology (Zurich, Switzerland)January 1, 2022Tauziède-Espariat A, Sievers P, Larousserie F, Benzakoun J, Guillemot D, Pierron G, Duchesne M, Uro-Coste E, Roux A, Vasiljevic A, et al.

(7) Antagonistic Roles of the Tumor Suppressor miR-210-3p and Oncomucin MUC4 Forming a Negative Feedback Loop in Pancreatic AdenocarcinomaCancersDecember 9, 2021Boukrout N, Souidi M, Lahdaoui F, Duchêne B, Neve B, Coppin L, Leteurtre E, Torrisani J, Van Seuningen I, Jonckheere N.

(8) Primary sclerosing epithelioid fibrosarcoma of the spine: a single-institution experienceHistopathologyJune 1, 2021Righi A, Pacheco M, Pipola V, Gambarotti M, Benini S, Sbaraglia M, Frisoni T, Boriani S, Dei Tos AP, Gasbarrini A.

(9) Diffuse expression of MUC6 defines a distinct clinicopathological subset of pulmonary invasive mucinous adenocarcinomaModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncApril 1, 2021Kishikawa S, Hayashi T, Saito T, Takamochi K, Kohsaka S, Sano K, Sasahara N, Sasa K, Kurihara T, Hara K, et al.

(10) Effect of decalcification protocols on immunohistochemistry and molecular analyses of bone samplesModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncAugust 1, 2020Miquelestorena-Standley E, Jourdan ML, Collin C, Bouvier C, Larousserie F, Aubert S, Gomez-Brouchet A, Guinebretière JM, Tallegas M, Brulin B, et al.

(11) Immunohistochemical and genetic analysis of respiratory epithelial adenomatoid hamartomas and seromucinous hamartomas: are they precursor lesions to sinonasal low-grade tubulopapillary adenocarcinomas?Human pathologyMarch 1, 2020Baněčková M, Michal M, Laco J, Leivo I, Ptáková N, Horáková M, Michal M, Skálová A.

(12) Intracytoplasmic Lumen in Urine Cytology Predicts Worse Prognosis in Non-Muscle-Invasive Bladder CancersActa cytologicaJanuary 1, 2020Terauchi T, Nakada S, Takenaka M, Mizuguchi S, Okanemasa Y, Tsubata Y, Miyazawa K, Kinjo M, Shioya A, Guo X, et al.

(13) Immunohistochemistry as a Genetic Surrogate in Dermatopathology: Pearls and PitfallsAdvances in anatomic pathologyNovember 1, 2019Oh KS, Mahalingam M.

(14) Neuroblastoma-like schwannoma with giant rosette: A potential diagnostic pitfall for hyalinizing spindle cell tumorJournal of cutaneous pathologyMarch 1, 2019Koubaa Mahjoub W, Jouini R, Khanchel F, Ben Brahim E, Llamas-Velasco M, Helel I, Khayat O, Chadli A, Badri T, Mentzel T.

(15) MUC4 expression in meningiomas: under-recognized immunophenotype particularly in meningothelial and angiomatous subtypesHistopathologyJanuary 1, 2019Matsuyama A, Jotatsu M, Uchihashi K, Tsuda Y, Shiba E, Haratake J, Hisaoka M.

(16) Expanding the spectrum of pediatric NTRK-rearranged fibroblastic tumors to the central nervous system: A case report with RBPMS-NTRK3 fusionNeuropathology : official journal of the Japanese Society of NeuropathologyDecember 1, 2018Torre M, Jessop N, Hornick JL, Alexandrescu S.

(17) EWSR1-SMAD3-rearranged Fibroblastic Tumor: An Emerging Entity in an Increasingly More Complex Group of Fibroblastic/Myofibroblastic NeoplasmsThe American journal of surgical pathologyOctober 1, 2018Michal M, Berry RS, Rubin BP, Kilpatrick SE, Agaimy A, Kazakov DV, Steiner P, Ptakova N, Martinek P, Hadravsky L, et al.

(18) Intraductal Papillary Mucinous Neoplasms of Minor Salivary Glands With AKT1 p.Glu17Lys MutationThe American journal of surgical pathologyAugust 1, 2018Agaimy A, Mueller SK, Bumm K, Iro H, Moskalev EA, Hartmann A, Stoehr R, Haller F.

(19) "RREB1-MKL2 fusion in biphenotypic ""oropharyngeal"" sarcoma: New entity or part of the spectrum of biphenotypic sinonasal sarcomas?"Genes, chromosomes & cancerApril 1, 2018Siegfried A, Romary C, Escudié F, Nicaise Y, Grand D, Rochaix P, Barres B, Vergez S, Chevreau C, Coindre JM, et al.

(20) Correlation of Tn antigen expression with mucins in Chinese patients with colorectal cancerInternational journal of clinical and experimental pathologyJanuary 1, 2018Jiang Y, Liu Z, Hu Y, Gao T, Wen T, An G.

Be the First to Write a Review!

Mucin 4 (8G7) Antibody

Mucin 4 (8G7) Antibody from Santa Cruz Biotechnology, Inc.

Description

Questions and Answers

Santa Cruz Biotechnology, Inc.

Citations (61)

Reviews

Mucin 4 (8G7) Antibody from Santa Cruz Biotechnology, Inc.

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map